The Impact of AbbVie's Market Control on the Future of Biosimilars
Friday, 7 June 2024, 12:25
AbbVie's Dominance of the Humira Market
The tight control that AbbVie has maintained over the Humira market is a point of contention for many industry experts.
Concerns about Biosimilars
AbbVie's dominance sparks worries regarding the potential competition biosimilars could pose in the future.
Market Share and Viability
Questions arise on the ability of biosimilars to challenge AbbVie's stronghold in the market and create more accessible options for patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.